Single cell RNA sequencing of murine hearts after acute proteasome inhibition
Ontology highlight
ABSTRACT: Bortezomib (BTZ), Carfilzomib (CFZ) and Ixazomib (IXA) are proteasome inhibitors (PI) approved for Multiple Myeloma (MM) treatment. By design, they all target the rate-limiting proteasome beta 5 (B5) subunit. CFZ treatment increases the survival of patients with relapsed/refractory MM compared to BTZ but is associated with heart failure not commonly observed for BTZ. The molecular basis for CFZ-induced cardiotoxicity is poorly understood. We time to investigate the transcriptomic effects of acute proteasome inhibition in the murine heart.
INSTRUMENT(S): Illumina NovaSeq 6000
ORGANISM(S): Mus musculus
SUBMITTER: Mechthild Lütge
PROVIDER: E-MTAB-11028 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA